We are live on ! Find out more
BBLG

Bone Biologics
BBLG

3 hedge funds and large institutions have $20.8K invested in Bone Biologics in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

1.65% less ownership

Funds ownership: 2.45% → 0.8% (-1.7%)

50% less funds holding

Funds holding: 6 → 3 (-3)

63% less capital invested

Capital invested by funds: $55.8K → $20.8K (-$35K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
3
Holders Change
-3
Holders Change %
-50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.55K
2
Bank of America
Bank of America
North Carolina
+$6

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$20.6K
2
HF
HRT Financial
New York
-$13K
3
Citigroup
Citigroup
New York
-$4.65K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.51K

BBLG Hedge Fund Activity: Q1 2025 in Review

3 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q1 2025, worth a combined $20.8K — down 63% from $55.8K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BBLG and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $8.55K. The largest seller was UBS Group, exiting entirely with an estimated $20.6K sold.

  • 3 institutional investors held Bone Biologics (BBLG) as of Q1 2025, down from 6 in Q4 2024.
  • Funds reported $20.8K of Bone Biologics stock for Q1 2025, down 63% quarter-over-quarter.
  • 0 funds opened new Bone Biologics positions in Q1 2025 and 3 closed out, a net change of -3 holders.
  • The largest Bone Biologics buyer in Q1 2025 was Geode Capital Management, an estimated $8.55K added.
  • The largest Bone Biologics seller in Q1 2025 was UBS Group, an estimated $20.6K sold.

Based on aggregated 13F filings for Q1 2025.